Clinical Trial

Dexmedetomidine Ropivacaine Versus Plain Ropivacaine in Bilateral Pectoralis Nerve (PECS) Block

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 15, 2024 (before its estimated December 31, 2024 completion). Its status may not reflect the trial's current state.
Summary
In 2012 Blanco et al. \[1\] described the ultrasound technique for Pectoral nerve (PECS) block as a new, less invasive regional analgesic technique for breast surgeries. PECS block includes PECS I and PECS II (modified PECS I) interfascial blocks. Since that time, PECS block has been used successfully with good results for a wide variety of surgeries on the chest wall such as radical mastectomies, breast-conserving surgeries, breast implant placement, automated implantable cardioverter-defibrillator (AICD)/pacemaker placement, intercostal drainage tube placement, and rib fractures. In this study, the investigators hypothesized that adding dexmedetomidine as an adjuvant to ropivacaine can result in the prolongation of the duration of anesthesia with improvement of the quality of postoperative analgesia of bilateral PECS block for patients undergoing cardiac surgery via midline sternotomy compared with using only plain ropivacaine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-10-09.
Status change: Not Yet Recruiting → Recruiting 2024-10-09
Trial Details
NCT Number NCT06636578
Lead Sponsor Fayoum University
Conditions Analgesia
Enrollment 90 participants
Start Date 2024-10-10
Primary Completion 2024-12-31 (estimated)
Study Completion 2025-01-08 (estimated)
Updated on ClinicalTrials.gov 2024-10-15